Skip to content

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520417-41-00
Acronym
222725
Enrollment
327
Registered
2025-11-24
Start date
2026-01-07
Completion date
Unknown
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Annualized Rate of Moderate/Severe Exacerbations

Detailed description

1. Time to First Moderate/Severe Exacerbation, 2. Change from Baseline in St. George’s Respiratory Questionnaire (SGRQ) Total Score at Week 52, 3. Change from Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52, 4. Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, 5. Annualized Rate of Severe Exacerbations

Interventions

Sponsors

Glaxosmithkline Research & Development Limited
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Annualized Rate of Moderate/Severe Exacerbations

Secondary

MeasureTime frame
1. Time to First Moderate/Severe Exacerbation, 2. Change from Baseline in St. George’s Respiratory Questionnaire (SGRQ) Total Score at Week 52, 3. Change from Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) Total Score at Week 52, 4. Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, 5. Annualized Rate of Severe Exacerbations

Countries

Austria, Bulgaria, Czechia, Germany, Greece, Italy, Latvia, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026